The Development of Second-Generation KRAS Inhibitors

H&O How common are KRAS mutations in patients with various types of cancer? EO Approximately 20% to 25% of patients with cancer will have a RAS […]

How to Implement DPYD Genotyping Into Practice

H&O Can you explain what the dihydropyrimidine dehydrogenase (DPYD) gene does? AV The DPYD gene encodes the dihydropyrimidine dehydrogenase (DPD) enzyme, which degrades excess thymine and […]

New Drugs for Relapsed or Refractory Multiple Myeloma

H&O What are the most recent drug approvals for relapsed or refractory myeloma? BD We have seen an influx of immunotherapies for relapsed or refractory myeloma […]

Adoptive Cell Therapy for Ovarian Cancer

H&O What are the shortcomings of existing therapies for ovarian cancer? KO Standard therapy in patients with newly diagnosed ovarian cancer consists of neoadjuvant chemotherapy followed […]

Access to Novel Cancer Drugs in Low- and Middle-Income Countries

H&O What are the biggest barriers preventing patients with cancer in India from accessing novel drugs? AP Accessing novel cancer drugs in India remains a major […]

FDA Regulatory Pathways for Expedited Drug Development and Approval

H&O What are the main expedited pathways for drug approval? ASK The main expedited regulatory pathways for the development and approval of prescription drugs by the […]

Reducing Drug Toxicity and Costs Through Off-Label Dosing

H&O What is wrong with the way doses are currently determined for oncology drugs? MR The US Food and Drug Administration (FDA) has approved many oncology […]

Intrathecal Immunotherapy in Patients Who Have Melanoma With Leptomeningeal Disease

H&O What is the rationale behind the use of immunotherapy for intrathecal treatment of leptomeningeal disease (LMD)? ICG When we talk about treatments before the new […]

The Development of ATR Inhibitors

H&O What is the ataxia telangiectasia and Rad3-related (ATR) protein, and what makes it a good target in cancer? TY The ATR protein is a serine […]

Ethics in Medicine: Avoiding Conflicts of Interest in Prescribing

H&O What are some potential sources of conflict of interest that physicians may encounter in prescribing? GVN The main conflict of interest is the one that […]

Tackling the Cancer Drug Shortage

H&O How bad is the chemotherapy drug shortage right now? EF The shortage is difficult to quantify. We do not know exactly how many patients’ therapy […]

The Global Cardio-Oncology Registry

H&O How did the field of cardio-oncology come about? DS There are about 20 million cancer survivors in the United States. With significant improvements in immunotherapy, […]

STING Activators in Cancer Care

H&O What are STING activators, and how do they play a role in cancer immunotherapy? RS The stimulator of interferon genes (STING) pathway plays a crucial […]

New Drug Approvals for Prostate Cancer

H&O What are the most recent drug approvals for prostate cancer? IT The most recent drug approvals for men with prostate cancer primarily consist of “me-too” […]

PROTAC Drugs in Cancer Care

H&O What are PROTACs, and how do they target proteins in cancer treatment? PF Proteolysis-targeting chimeras (PROTACs) are a new class of drugs that, in my […]

Coordination Between the FDA and the US Patent and Trademark Office

H&O What is the Executive Order on Promoting Competition in the American Economy and how does it relate to coordination between the FDA and the USPTO? […]

The Impact of Financial Toxicity on Cancer Care

H&O What is financial toxicity, and how does it impact cancer therapy? JP Financial toxicity is a term used to describe the burdens, barriers, and distress […]

Repurposing Drugs in Oncology

H&O What is drug repurposing, and how is it used in oncology? EV Drug repurposing describes the phenomenon of using drugs that are already approved or […]

Novel Sources of Funding for Clinical Trials in Oncology

H&O What are the traditional sources of funding for clinical trials in oncology, and how have they evolved over time? GS Traditional sources of funding for […]

Dosing of Nivolumab in India

H&O What factors determine the appropriate dose of nivolumab? VN The dosing of any drug is determined by multiple factors. Traditionally, drug dosing is initially determined […]